What this means
Heart failure is characterised by increased production of reactive oxygen species (ROS), which contribute to apoptotic signalling. Changes in excitation-contraction coupling in heart failure promote increased calcium extrusion and decreased calcium uptake by myocardial mitochondria.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Earlier studies
- Kind of research
- A summary of earlier studies
The science
- Original title
- The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets.
- Authors
- Hussain T, Pandey A, Karki D et al.
- Journal
- Cureus
- Published
- Jul 24, 2026
- Study type
- Review
- PMID
- 42495453 ↗
Abstract
Heart failure is characterised by increased production of reactive oxygen species (ROS), which contribute to apoptotic signalling. Changes in excitation-contraction coupling in heart failure promote increased calcium extrusion and decreased calcium uptake by myocardial mitochondria. Mitochondrial calcium is required to increase the Krebs cycle flux to generate sufficient nicotinamide adenine dinucleotide (NADH) to match the increased energy demand seen in heart failure. Reduced NADH availability can decrease levels of reduced nicotinamide adenine dinucleotide phosphate (NADPH), leading to a loss of NADPH-mediated antioxidant capacity and thereby increasing ROS emission and oxidative damage. Accordingly, a group of therapies that increase mitochondrial calcium, such as sodium glucose-linked transporter 2 inhibitors and ranolazine, have been investigated as potential treatments in heart failure. Proposed mechanisms include reducing calcium extrusion from mitochondria via the Na+/Ca2+/Li+ exchanger. A second group of emerging therapies targets oxidative stress by directly scavenging ROS (MitoQ and SS-31) and has also been studied for use in heart failure. Contemporary research developments propose an alternative approach to targeting oxidative stress by enhancing endogenous antioxidant capacity through the administration of nicotinamide adenine dinucleotide (NAD) precursors, thereby increasing intracellular NAD availability.
Hussain T, Pandey A, Karki D et al. The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets. Cureus. 2026. doi:10.7759/cureus.111384. PMID: 42495453. https://pubmed.ncbi.nlm.nih.gov/42495453/
Related research
A peptide eased signs of aging in heart cells damaged by a cancer drug
Researchers treated heart muscle cells in a dish with a cancer drug, then a peptide called SS-31. The peptide reduced several signs of aging, but not cell cycle arrest. This was done only in lab cells, so it does not show the peptide would help people.
Two drugs together eased stroke brain damage in mice
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Peptide SS-31 eased radiation-caused aging signs in heart cells
Researchers exposed heart cells to radiation and gave some of them SS-31. SS-31 reduced several aging signs, but this was only tested in cells, not people.
Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society.
Two mitochondria-targeted drugs studied in aged female mice with fatty liver disease
Researchers gave two drugs to older mice with fatty liver disease caused by a rich diet. Both drugs improved liver markers in the mice, but this does not show they would help people.
The Oxidative-Mitochondrial-Inflammatory Axis in Retinitis Pigmentosa: Extracellular mtDNA as Biomarker and Therapeutic Read-Out.
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy (prevalence ~1:4000) and a leading Mendelian cause of working-age blindness.
See all research on Elamipretide (SS-31) →